Effect of Hyperglycemia on COVID-19 Outcomes: Vaccination Efficacy, Disease Severity, and Molecular Mechanisms DOI Open Access
Celestino Sardu, Raffaele Marfella, Francesco Prattichizzo

et al.

Journal of Clinical Medicine, Journal Year: 2022, Volume and Issue: 11(6), P. 1564 - 1564

Published: March 12, 2022

Background/Aims: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-stranded single-stranded RNA virus, member of the subgenus Sarbecovirus (beta-CoV lineage B) and responsible for disease 2019 (COVID-19). COVID-19 encompasses large range severity, from mild symptoms to forms with Intensive Care Unit admission eventually death. are usually observed in high-risk patients, such as those type two diabetes mellitus. Here, we review available evidence linking chronic hyperglycemia outcomes, describing also putative mediators interactions. Findings/Conclusions: Acute at hospital represents risk factor poor prognosis patients without diabetes. glycemic control both emerging major determinants vaccination efficacy, severity mortality rate patients. Mechanistically, it has been proposed that might be disease-modifier through multiple mechanisms: (a) induction glycation oligomerization ACE2, main receptor SARS-CoV-2; (b) increased expression serine protease TMPRSS2, S protein priming; (c) impairment function innate adaptive immunity despite higher pro-inflammatory responses, local systemic. Consistently, managing insulin infusion suggested improve clinical while implementing positively affects immune response following vaccination. Although more research warranted better disentangle relationship between COVID-19, worth considering potential route optimize prevention management.

Language: Английский

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023 DOI Open Access
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda

et al.

Diabetes Care, Journal Year: 2022, Volume and Issue: 46(Supplement_1), P. s49 - s67.2

Published: Dec. 12, 2022

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating Standards annually, or more frequently as warranted. For detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.

Language: Английский

Citations

155
Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study DOI Creative Commons
Abdullah Alguwaihes, Mohammed E. Al‐Sofiani,

Maram Megdad

et al.

Cardiovascular Diabetology, Journal Year: 2020, Volume and Issue: 19(1)

Published: Dec. 1, 2020

Abstract Background Information on the clinical characteristics and outcomes of hospitalized Covid-19 patients with or without diabetes mellitus (DM) is limited in Arab region. This study aims to fill this gap. Methods In single-center retrospective study, medical records adults confirmed [RT-PCR positive for SARS-CoV2] at King Saud University Medical City (KSUMC)-King Khaled Hospital (KKUH), Riyadh, Saudi Arabia from May July 2020 were analyzed. Clinical, radiological serological information, as well recorded Results A total 439 included (median age 55 years; 68.3% men). The most prevalent comorbidities vitamin D deficiency (74.7%), DM (68.3%), hypertension (42.6%) obesity (42.2%). During hospitalization, 77 out (17.5%) died. have a significantly higher death rate (20.5% versus 12.3%; p = 0.04) lower survival time (p 0.016) than non-DM. Multivariate cox proportional hazards regression model revealed that [Hazards ratio, HR 3.0 (95% confidence interval, CI 1.7–5.3); < 0.001], congestive heart failure [adjusted 3.5 (CI 1.4–8.3); 0.006], smoking 5.8 2.0–17.2); β-blocker use 1.7 1.0–2.9); 0.04], bilateral lung infiltrates 1.9 1.1–3.3); 0.02], creatinine > 90 µmol/l 2.1 1.3–3.5); 0.004] 25(OH)D 12.5 nmol/l 7.0 1.7–28.2); 0.007] significant predictors mortality among patients. Random blood glucose ≥ 11.1 mmol/l was associated intensive care admission 1.5 1.0–2.2); smoking, use, neutrophil 7.5, alanine aminotransferase 65U/l. Conclusion prevalence high Arabia. While their non-DM counterparts, other factors such old age, failure, presence infiltrates, elevated severe deficiency, appear be more fatal outcome. Patients acute metabolic dysfunctions, including hyperglycemia are likely receive care.

Language: Английский

Citations

147
COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus DOI Creative Commons
Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Mohamd A. Alblihed

et al.

Frontiers in Cardiovascular Medicine, Journal Year: 2021, Volume and Issue: 8

Published: May 20, 2021

Coronavirus disease 2019 (COVID-19), triggered by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), may lead to extrapulmonary manifestations like diabetes mellitus (DM) and hyperglycemia, both predicting a poor prognosis an increased risk of death. SARS-CoV-2 infects pancreas through angiotensin-converting enzyme (ACE2), where it is highly expressed compared other organs, leading pancreatic damage with subsequent impairment insulin secretion development hyperglycemia even in non-DM patients. Thus, this review aims provide overview potential link between COVID-19 as factor for DM relation pharmacotherapy. For that, systematic search was done database MEDLINE Scopus, Web Science, PubMed, Embase, China National Knowledge Infrastructure (CNKI), Biology Medicine (CBM), Wanfang Data. Data obtained underline that infection patients more associated clinical outcomes due preexistence comorbidities inflammation disorders. impairs glucose homeostasis metabolism cytokine storm (CS) development, downregulation ACE2, direct injury β-cells. Therefore, potent anti-inflammatory effect diabetic pharmacotherapies such metformin, pioglitazone, sodium-glucose co-transporter-2 inhibitors (SGLT2Is), dipeptidyl peptidase-4 (DPP4) mitigate severity. In addition, some antidiabetic agents also reduce infectivity severity modulation ACE2 receptor expression. The findings presented here illustrate therapy might seem appropriate than anti-DM management low uncontrolled ketoacidosis (DKA). From these findings, we could not give final conclusion about efficacy pharmacotherapy COVID-19; thus, trial prospective studies are warranted confirm finding concern.

Language: Английский

Citations

109
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024 DOI Open Access
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru

et al.

Diabetes Care, Journal Year: 2023, Volume and Issue: 47(Supplement_1), P. S52 - S76

Published: Dec. 11, 2023

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating Standards annually, or more frequently as warranted. For a detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.

Language: Английский

Citations

79
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication DOI Creative Commons
Qin Ning, Di Wu, Xiaojing Wang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Feb. 23, 2022

Abstract The coronavirus disease 2019 (COVID-19) is a highly transmissible caused by the severe acute respiratory syndrome 2 (SARS-CoV-2) that poses major threat to global public health. Although COVID-19 primarily affects system, causing pneumonia and distress in cases, it can also result multiple extrapulmonary complications. pathogenesis of damage patients with probably multifactorial, involving both direct effects SARS-CoV-2 indirect mechanisms associated host inflammatory response. Recognition features complications has clinical implications for identifying progression designing therapeutic strategies. This review provides an overview from immunological pathophysiologic perspectives focuses on potential targets management COVID-19.

Language: Английский

Citations

73
The impact of the COVID-19 pandemic on diabetes services: planning for a global recovery DOI
Kamlesh Khunti, Vanita R. Aroda, Pablo Aschner

et al.

The Lancet Diabetes & Endocrinology, Journal Year: 2022, Volume and Issue: 10(12), P. 890 - 900

Published: Nov. 7, 2022

Language: Английский

Citations

73
Impact of COVID-19 and comorbidities on health and economics: Focus on developing countries and India DOI Open Access
Awadhesh Kumar Singh, Anoop Misra

Diabetes & Metabolic Syndrome Clinical Research & Reviews, Journal Year: 2020, Volume and Issue: 14(6), P. 1625 - 1630

Published: Aug. 27, 2020

Language: Английский

Citations

127
Health literacy, preventive COVID 19 behaviour and adherence to chronic disease treatment during lockdown among patients registered at primary health facility in urban Jodhpur, Rajasthan DOI Open Access
Vaishali Gautam,

S. Dileepan,

Neeti Rustagi

et al.

Diabetes & Metabolic Syndrome Clinical Research & Reviews, Journal Year: 2020, Volume and Issue: 15(1), P. 205 - 211

Published: Dec. 30, 2020

Language: Английский

Citations

77
Hyperglycemia and COVID-19: What was known and what is really new? DOI Creative Commons
Antonio Ceriello

Diabetes Research and Clinical Practice, Journal Year: 2020, Volume and Issue: 167, P. 108383 - 108383

Published: Aug. 25, 2020

Diabetes is one of the most relevant co-morbidity in worsening prognosis COVID-19 [1Caballero A.E. Ceriello A. Misra et al.COVID-19 people living with diabetes: an international consensus.J Complications. 2020; 34107671https://doi.org/10.1016/j.jdiacomp.2020.107671Crossref PubMed Scopus (93) Google Scholar]. Data also showing that hyperglycemia, both or without diabetes, important risk factor for death [2Sing Hyperglycemia diabetes and new-onset are associated poorer outcomes COVID-19. Diab Res Clin Pract 2020;167:108382.Google Scholar, 3Cariou B. Hadjadj S. Wargny M. al.CORONADO investigators. Phenotypic characteristics inpatients CORONADO study.Diabetologia. 63https://doi.org/10.1007/s00125-020-05180-xCrossref (589) 4Wu J. Huang Zhu G. al.Elevation blood glucose level predicts worse hospitalized patients COVID-19: a retrospective cohort study.BMJ Open Care. 8e001476https://doi.org/10.1136/bmjdrc-2020-001476Crossref (99) 5Zhu L. She Z.G. Cheng X. al.Association control pre-existing Type 2 diabetes.Cell Metab. 31: 1068-1077https://doi.org/10.1016/j.cmet.2020.04.021Abstract Full Text PDF (1104) Sing reporting some aspects this finding In summary, evidence shows:1.That hyperglycemia at time hospital admission more as than previous glycemic evaluated by HbA1c This emerges particularly from Study (Coronavirus SARS-CoV-2 Outcomes), French nationwide multicentre observational study, aiming to identify clinical biological features disease severity mortality hospitalised [3Cariou Scholar].2.That seems However, it worth mention variability during hospitalization, non-diabetes, emerged independent [4Wu According evidence, clear acute has key role raised great interest, being considered somehow new finding. how much it? Already, SARS epidemic, factors [6Yang J.K. Feng Y. Yuan M.Y. al.Plasma levels predictors morbidity SARS.Diabet Med. 2006; 23: 623-628https://doi.org/10.1111/j.1464-5491.2006.01861.xCrossref (538) The specific HbA1c, well known Intensive Care Units (ICU), where increased gap between HbA1 been found predictor critically ill [7Liao W.I. Wang J.C. Chang W.C. Hsu C.W. Chu C.M. Tsai S.H. Usefulness predict ICU diabetes.Medicine (Baltimore). 2015; 94: e1525https://doi.org/10.1097/MD.0000000000001525Crossref (55) 8Su Y.W. C.Y. Guo Chen H.S. plasma concentration-to-HbA 1c ratio predicting illness extreme hyperglycaemia.Diabetes 2017; 43https://doi.org/10.1016/j.diabet.2016.07.036Crossref (34) impact (stress) very [9Bellaver P. Schaeffer A.F. Dullius D.P. multiple parameters intensive care unit patients.Sci Rep. 2019; 9: 18498https://doi.org/10.1038/s41598-019-55080-3Crossref (33) Moreover, dangerous [10Chang M.W. Liu H.T. Y.C. Hsieh C.H. Stress-induced diabetic higher among Unit Trauma Patients: cross-Sectional analysis propensity score-matched population.Int J Environ Public Health. 2018; 15: 992https://doi.org/10.3390/ijerph15050992Crossref (25) Acute induces inflammation, endothelial dysfunction thrombosis, through generation oxidative stress [11Ceriello hyperglycaemia: 'new' myocardial infarction.Eur Heart 2005; 26: 328-331https://doi.org/10.1093/eurheartj/ehi049Crossref (126) chronic stress, inducing increase antioxidant defences cells therefore, spike tissues protected [12Ceriello dello Russo Amstad Cerutti High enzymes human culture. Evidence linking stress.Diabetes. 1996; 45: 471-477https://doi.org/10.2337/diab.45.4.471Crossref (315) not case absence exposing damage. vitro experiments were able demonstrate miRNAs phenomenon [13La Sala Mrakic-Sposta Micheloni Prattichizzo F. Glucose-sensing microRNA-21 disrupts ROS homeostasis impairs responses cellular variability.Cardiovasc Diabetol. 17: 105https://doi.org/10.1186/s12933-018-0748-2Crossref (66) what described above, question why worsens COVID-19, but so frequent. For example, reported occurs about 50% while prevalence same population was 7% [14Li Xu Yu al.Risk adult Wuhan.J Allergy Immunol. 146: 110-118https://doi.org/10.1016/j.jaci.2020.04.006Abstract (1519) A possible hypothesis "Severe respiratory syndrome coronavirus 2" (SARS-CoV-2)" may affect pancreatic β-cells producing reduction insulin secretion [15Ceriello De Nigris V. Why hyperglycaemia its prognosis?.Diabetes Obes https://doi.org/10.1111/dom.14098. 10.1111/dom.14098Crossref At time, infection accompanied huge production cytokines, which induce resistance Both, reduced resistance, hesitate conclusion, effect surprising should be treated according already existing guidelines [16Ceriello fast mandatory.Diabetes Pract. 163https://doi.org/10.1016/j.diabres.2020.108186Abstract (60) 17Ceriello Standl E. Catrinoiu D. al."Diabetes Cardiovascular Disease (D&CVD)" Group European Association (EASD). Issues management ICU.Cardiovasc 19https://doi.org/10.1186/s12933-020-01089-2Crossref (35) 18Ceriello al.Diabetes (D&CVD) EASD Group. cardiovascular era.Diabetes 43https://doi.org/10.2337/dc20-0941Crossref (67) Conflict Interest: AC does have conflicts interest declare. None.

Language: Английский

Citations

72
High prevalence of diabetes and other comorbidities in hospitalized patients with COVID-19 in Delhi, India, and their association with outcomes DOI Open Access
Ambrish Mithal, Ganesh Jevalikar,

Rutuja Sharma

et al.

Diabetes & Metabolic Syndrome Clinical Research & Reviews, Journal Year: 2020, Volume and Issue: 15(1), P. 169 - 175

Published: Dec. 18, 2020

Language: Английский

Citations

71